Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 11/20 | 0.52 |
| ▸ | DRD4 | P21917 | 11/20 | 0.52 |
| ▸ | DRD3 | P35462 | 11/20 | 0.52 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437765 | 0.96 | BCHE (0.59) | BCHEDRD2DRD4DRD3UTS2R | |
| SCHEMBL12437763 | 0.91 | UTS2R (0.51) | DRD2DRD4DRD3UTS2RHDAC3 | |
| SCHEMBL12437664 | 0.87 | HDAC3 (0.58) | BCHEDRD2DRD4DRD3HDAC3 | |
| SCHEMBL12437581 | 0.86 | MEN1 (0.59) | BCHEDRD2DRD4DRD3HDAC3 | |
| SCHEMBL12437764 | 0.84 | UTS2R (0.64) | DRD2DRD4DRD3UTS2R | |
| SCHEMBL12437535 | 0.83 | BCHE (0.61) | BCHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12513576 | 0.83 | BCHE (0.61) | BCHEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12437746 | 0.82 | OPRK1 (0.45) | UTS2R | |
| SCHEMBL12437536 | 0.81 | BCHE (0.52) | BCHEDRD2DRD4DRD3 | |
| SCHEMBL12437948 | 0.81 | SLC5A7 (0.56) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | BCHE 3384/4885DRD2 1842/4885DRD4 1789/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | BCHE 3384/4885DRD2 1842/4885DRD4 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.